Cogent Biosciences Inc at Needham Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. I'm Ami Fadia, one of the biotech analysts here at Needham. It's my pleasure to be hosting for our next session, Cogent Biosciences. We've got Andy Robbins who's President and CEO of the company.
Andy, thank you so much for taking the time to join us today. I suppose to just get us started, if you could provide us a quick overview of the company just for those who are not very familiar, and we'll dive straight into Q&A.
Sure. That sounds great. And first of all, thanks for inviting us. We're happy to be here and look forward to the conversation. Just for the folks listening, and I'll remind people that I probably will be making forward-looking statements during the conversation today. So for a more full characterization of the risks specific to the company, we just point you to our recent SEC disclosures. With that said, we're excited to be here. And
As you mentioned, I'm Andy. I'm the CEO of Cogent. We are a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
